Preferred Label : Azintuxizumab Vedotin;
NCIt synonyms : ADC ABBV-838;
NCIt definition : An antibody-drug conjugate (ADC) composed of an antibody targeting CS1 (SLAMF7/CD319)
that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin
E (MMAE), via a cathepsin-cleavable linker, with potential antineoplastic activity.
Upon administration, the antibody moiety of azintuxizumab vedotin binds to CS1-expressing
tumor cells and is internalized, thereby delivering MMAE intracellularly. Upon cleavage,
MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint
arrest and apoptosis in CS1-expressing tumor cells. CS1 is a cell surface glycoprotein
belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is expressed
with high levels and prevalence on multiple myeloma (MM) cells.;
UNII : 6XQ9TM3U2G;
CAS number : 1826819-58-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1826819-58-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : ABBV-838;
Origin ID : C122816;
UMLS CUI : C5139883;
Semantic type(s)
- concept_is_in_subset
- has_target
